Abstract
Hemostatic balance is regulated by many factors that may become perturbed by cardio-metabolic abnormalities. Indeed, patients with multiple components of the metabolic syndrome have increased risk of atherosclerosis, hemostatic disorders and thrombotic events. This review focuses on the interrelationship between the metabolic syndrome components and thrombotic and thromboembolic events, the potential underlying mechanisms that lead to metabolic and hemostatic disorders in metabolic syndrome patients, the existing therapeutics aimed at reducing major cardiovascular events, and new therapeutic approaches to address pro-coagulant states.
Keywords: Metabolic syndrome, hemostatis, thrombosis, coagulation, cardiovascular disease, diabetes, cardio-metabolic abnormalities, metabolic syndrome patients, thromboembolic events, cardiovascular risk, coronary atheroma progression, Elevated triglyceride-rich VLDL, adipocyte dysfunction, coronary heart disease (CHD)
Current Pharmaceutical Biotechnology
Title: Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis
Volume: 12 Issue: 9
Author(s): Laura F. Michael, Veena Rao, Patrick McCollam, Mark C. Kowala and John Wetterau
Affiliation:
Keywords: Metabolic syndrome, hemostatis, thrombosis, coagulation, cardiovascular disease, diabetes, cardio-metabolic abnormalities, metabolic syndrome patients, thromboembolic events, cardiovascular risk, coronary atheroma progression, Elevated triglyceride-rich VLDL, adipocyte dysfunction, coronary heart disease (CHD)
Abstract: Hemostatic balance is regulated by many factors that may become perturbed by cardio-metabolic abnormalities. Indeed, patients with multiple components of the metabolic syndrome have increased risk of atherosclerosis, hemostatic disorders and thrombotic events. This review focuses on the interrelationship between the metabolic syndrome components and thrombotic and thromboembolic events, the potential underlying mechanisms that lead to metabolic and hemostatic disorders in metabolic syndrome patients, the existing therapeutics aimed at reducing major cardiovascular events, and new therapeutic approaches to address pro-coagulant states.
Export Options
About this article
Cite this article as:
F. Michael Laura, Rao Veena, McCollam Patrick, C. Kowala Mark and Wetterau John, Opportunities for Pharmacotherapy at the Intersection of Metabolic Syndrome and Hemostasis, Current Pharmaceutical Biotechnology 2011; 12 (9) . https://dx.doi.org/10.2174/138920111798281081
DOI https://dx.doi.org/10.2174/138920111798281081 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |
Call for Papers in Thematic Issues
Artificial Intelligence in Bioinformatics
Bioinformatics is an interdisciplinary field that analyzes and explores biological data. This field combines biology and information system. Artificial Intelligence (AI) has attracted great attention as it tries to replicate human intelligence. It has become common technology for analyzing and solving complex data and problems and encompasses sub-fields of machine ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tapping into Mitochondria to Find Novel Targets for Diabetes Complications
Current Drug Targets Disseminated Intravascular Coagulation in Leukemia and Sepsis
Vascular Disease Prevention (Discontinued) Thromboembolic Complications in Malignant Haematological Disorders
Current Vascular Pharmacology Thrombophilia in Pregnancy: Maternal and Fetal Implications
Current Women`s Health Reviews 12-Lipoxygenase: A Potential Target for Novel Anti-Platelet Therapeutics
Cardiovascular & Hematological Agents in Medicinal Chemistry Detrimental Effects of Hyperglycemia in Acute Coronary Syndromes: from Pathophysiological Mechanisms to Therapeutic Strategies
Mini-Reviews in Medicinal Chemistry Big Science for Small Cells: Systems Approaches for Platelets
Current Drug Targets Polymer-Drug Nanoconjugate – An Innovative Nanomedicine: Challenges and Recent Advancements in Rational Formulation Design for Effective Delivery of Poorly Soluble Drugs
Pharmaceutical Nanotechnology Coronary Risk Assessment and Management Options in Chronic Kidney Disease Patients Prior to Kidney Transplantation
Current Cardiology Reviews Origin and Biological Significance of Shed-Membrane Microparticles
Endocrine, Metabolic & Immune Disorders - Drug Targets Body Mass Index in Midlife and Risk of Alzheimer Disease and Vascular Dementia
Current Alzheimer Research Simultaneous Genotyping of Four Single Nucleotide Polymorphisms Associated with Risk Factors of Hemostasis Disorders
Combinatorial Chemistry & High Throughput Screening Pathophysiology and Treatment of Diabetic Peripheral Neuropathy: The Case for Diabetic Neurovascular Function as an Essential Component
Current Diabetes Reviews Role of Thrombin Activatable Fibrinolysis Inhibitor in Endocrine and Cardiovascular Disorders: An Update
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Mechanisms Involved in the Genesis of Diabetic Nephropathy
Current Diabetes Reviews Diabetes and Antioxidants: Myth or Reality?
Current Vascular Pharmacology Role of Cellular Elements in Thrombus Formation and Dissolution
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Integrin-Specific Targets for Anti-Platelet Therapies
Current Pharmaceutical Design Pleiotropic Effects of PPARγ Agonist on Hemostatic Activation in Type 2 Diabetes Mellitus
Current Vascular Pharmacology Plasminogen Activator System and Vascular Disease
Current Vascular Pharmacology